F-STAR THERAPEUTICS INC NASDAQ:FSTX F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

Location: 35 Parkwood Dr Ste 210, Massachusetts, 01748-1699, US | Website: f-star.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing